cagrilintide patent Characterization of 0839 – A
Characterization of 0839 A tool compound for pre clinical mode of action studies of amylin analogues such as cagrilintide ScienceDirect In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide C194H312N54O59S2 CID 171397054 PubChem Novo Nordisk's CagriSema Leads to Superior Weight Loss in REDEFINE 1 Trial Updates in Medicine CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight Instagram
Pay in 4 interest-free payments of $7.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6


